Mutations in the EGFR also confer drug resistance in non-small cell lung cancer (NSCLC) and other tumor types (Cortot and Janne, 2014), e.g., the T790M mutation, alternative pathways activation, loss of function of the EGFR-mediated apoptosis pathway (Huang and Fu, 2015). Here, EGFR is linked to non-small cell lung carcinoma.